Pacific Biosciences
PACB
262 hedge funds and large institutions have $6.04B invested in Pacific Biosciences in 2021 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 97 increasing their positions, 71 reducing their positions, and 46 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 71
16% more call options, than puts
Call options by funds: $41.4M | Put options by funds: $35.7M
10% more capital invested
Capital invested by funds: $5.47B → $6.04B (+$565M)
1.94% more ownership
Funds ownership: 85.12% → 87.06% (+1.9%)
2% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 46
0% more funds holding
Funds holding: 262 → 262 (0)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$85.2M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$83.6M |
| 3 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$56M |
| 4 |
Goldman Sachs
New York
|
+$41M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
+$28.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$78.9M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$34M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$32M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$23.8M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$15.8M |
PACB Hedge Fund Activity: Q2 2021 in Review
262 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2021, worth a combined $6.04B — up 10% from $5.47B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new PACB positions and 46 closed out — a net gain of 1 holder — while 97 added to existing stakes and 71 trimmed.
The largest buyer was Sumitomo Mitsui Trust Group, adding an estimated $85.2M. The largest seller was Fidelity Investments, cutting an estimated $78.9M.
- 262 institutional investors held Pacific Biosciences (PACB) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $6.04B of Pacific Biosciences stock for Q2 2021, up 10% quarter-over-quarter.
- 47 funds opened new Pacific Biosciences positions in Q2 2021 and 46 closed out, a net change of +1 holder.
- The largest Pacific Biosciences buyer in Q2 2021 was Sumitomo Mitsui Trust Group, an estimated $85.2M added.
- The largest Pacific Biosciences seller in Q2 2021 was Fidelity Investments, an estimated $78.9M sold.
Based on aggregated 13F filings for Q2 2021.